Header Ads

The Chinese covid-19 vaccine provides a rapid immune response in four weeks

Although preliminary and intermediate tests have not been developed to evaluate the efficacy of CoronaVac, the researchers say it could provide adequate protection on the experience of other vaccines and data from McCabe's pre-clinical research.

Photographer: Jonne Roriz/Bloomberg


‌Sinovac Biotech Ltd. SARS-CoV-2 vaccine in Sao Paulo, Brazil, on Wednesday, Nov. 11, 2020. Brazil's decision to suspend efforts for the Synovac coronavirus vaccine was criticized. Photography: John Rorys / Bloomberg.

Sinovac Biotech’s CoronaVac Covid-19 vaccine test showed rapid immunity, but levels of antibodies produced were lower than on Wednesday's disease.

Although preliminary and intermediate tests have not been established to evaluate the effectiveness of Coronavac, researchers say it may provide adequate protection based on the experience of other vaccines and data from McCall Stennial Research.

This month, US and Russian pharmaceutical companies Pfizer and Modern said that experimental vaccines showed more than 90%, based on preliminary data from professors' large lab-stage trials.

CoronaVac and four other experimental vaccines developed by China are being tested at a late stage to determine their effectiveness in preventing COVID-19.

Senowak's findings, published in the peer-reviewed medical journal The Infectious Diseases Lancet in China I and II. Interim clinical trials were based on the results of more than 700 participants.

"Our results show that Coronavac vaccine is able to provide rapid antibody resistance within four weeks after vaccination within 1 to 4 days," said the authors of the article.

"We believe that vaccines are useful for immediate use in the event of an outbreak," Zhou said in a statement issued by the letter.

Researchers say that large-scale studies take place in size or three or so late. The results of stage evidence will be needed to determine whether the immunity produced by the coronavirus is sufficient to protect humans from coronavirus infection.

Synovac III. Indonesia, Brazil and Turkey are taking the test in three phases.

The results must be carefully explained III. Noah Bar-Ziv, a professor at Johns Hopkins University, said he would not take part in the study until the results of this phase were published.

"But until then, after the third phase of testing and licensing, we have to be careful," he said.

'Attractive Opportunity'

Coronavac China is one of three experimental Covid-1 vaccines being used to vaccinate hundreds of thousands of people as part of an emergency use program.

The review documents show two other vaccines from the Chinese emergency program, which have been developed by organizations affiliated with Synopharma, and another vaccine from Cancin Biologics that was safe for immune reactions in early and moderate trials.

The vaccine can be an attractive option because it can be kept at a normal refrigerator temperature of 2 to 8 degrees Celsius (36°-46°F) and stable for three years, ”said Zwang Zheng, a Synwac researcher involved in the CoronaVac study. 

“(It) will provide some benefits for reaching difficult areas of the refrigerator,” the author said.

Vaccines developed by Pfizer / Bioentech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require cold storage.

Pfizer vaccine should be stored at a temperature of -70 से C, although the refrigerator can usually be kept in a thermal container for five to 15 days. Modern filters are expected to remain stable at normal refrigerator temperatures for 30 days, but must be stored at -20C for up to six months.

Coronac is also being considered for vaccines in Brazil and Indonesia in the coming months.

In order to launch a massive vaccination campaign in Indonesia and the vaccines they have installed, they are demanding an emergency leave at the end of the year.

The Synovac and China will be used during the initial period of the Chinese Synopharm expedition.

Brazil’s Sao Paulo also plans to launch CoronaVac in January and has agreed to a supply agreement with SinoVac.

"CoronaVac's excellent safety, compared to other developmental vaccines, is gaining widespread acceptance from the public," said Ricardo Palacios, director of testing at the Biomedical Center at the Instituto Butanton in Brazil, where Coronavac is being tested.

No comments

Powered by Blogger.